Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim study finds HSDD tool effective

Boehringer Ingelheim study finds HSDD tool effective

3rd March 2009

Boehringer Ingelheim has funded a study that has determined a tool for diagnosing hypoactive sexual desire disorder (HSDD) is effective.

Standard procedures to determine whether a patient has this most common form of female sexual dysfunction can be time-consuming and require an extensive interview by a clinician.

It was thought by some in the industry that a simple tool was needed as it is a topic many are embarrassed about discussing and some medical professionals believe they do not have the necessary training to resolve the issue.

The development of the five-question survey, which requires yes or no answers, also followed a recommendation from the US Food and Drug Administration that noted a means was required to distinguish those with or without the disorder.

Lead author of the study Dr Anita Clayton commented: “This new tool can open up the dialogue, helping physicians and other clinicians to accurately diagnose generalised, acquired HSDD.”

The report is published in the Journal of Sexual Medicine.

With its headquarters in Germany, Boehringer Ingelheim operates globally with 135 affiliates in 47 countries.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.